Evidence map›Paper›PMID 42346029›Full record

ArticleEpigenomes2026

Olalekan Olatunde Fadebi, Babatunde Adebola Alabi, Richard Khanyile, Zodwa Dlamini, Rahaba Marima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Olalekan Olatunde FadebiDepartment of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Africa.ORCID 0000-0002-8449-4727
Babatunde Adebola AlabiDepartment of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Africa.
Richard KhanyileDepartment of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Africa.
Zodwa DlaminiSAMRC Precision Oncology Research Unit (PORU), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield, Pretoria 0028, South Africa.ORCID 0000-0002-8012-3646
Rahaba MarimaDepartment of Medical Oncology, Faculty of Health Sciences, Steve Biko Academic Hospital, University of Pretoria, Hatfield, Pretoria 0028, South Africa.ORCID 0000-0001-5050-7350

Funding

National Research Foundation NRF N1G655
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and the frequent emergence of therapeutic resistance. While the role of protein-coding genes in DNA repair is well-documented, the regulatory contributions of the non-coding genome, specifically long intergenic non-coding RNAs (lincRNAs), remain largely undefined.

objectivesIn this study, we characterize the biological significance of

methodsThrough a combined in silico and in vitro approach, we investigated the transcriptional dynamics of the

resultsOur results demonstrate that Olaparib induces selective cytotoxicity in

conclusionsBy sequestering

Indexed as

BRCA1breast cancerceRNALincRNA-BC7miR-663aolaparibPARP inhibitiontriple-negative breast cancer (TNBC)

Identifiers

PMID42346029
PMCPMC13298166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.